Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers.

Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, Parsons BM, Kenny PA, Matkowskyj KA, Newton MA, Skala MC, Deming DA.

Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.

PMID:
30425131
2.

HIV-1 Vif's Capacity To Manipulate the Cell Cycle Is Species Specific.

Evans EL 3rd, Becker JT, Fricke SL, Patel K, Sherer NM.

J Virol. 2018 Mar 14;92(7). pii: e02102-17. doi: 10.1128/JVI.02102-17. Print 2018 Apr 1.

Supplemental Content

Loading ...
Support Center